Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

Somatic ERBB2 amplification or activating mutations occur in approximately 2–5% of metastatic colorectal adenocarcinomas and are presumed to be oncogenic drivers, but limited evidence exists to suggest these lesions are sensitive to targeted monotherapy in patients. Here we present the case of a pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoscience
Main Authors: Disel, Umut, Germain, Alexis, Yilmazel, Bahar, Abali, Huseyin, Bolat, Filiz Aka, Yelensky, Roman, Elvin, Julia A., Lipson, Doron, Chmielecki, Juliann, Wang, Kai, Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., George, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4506361/
https://ncbi.nlm.nih.gov/pubmed/26244165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados